MXCT (MaxCyte, Inc. Common Stock) Stock Analysis - News
MaxCyte, Inc. Common Stock (MXCT) is a publicly traded Healthcare sector company. As of May 21, 2026, MXCT trades at $1.07 with a market cap of $113.55M and a P/E ratio of -2.49. MXCT moved +1.44% today. Year to date, MXCT is -30.97%; over the trailing twelve months it is -50.92%. Its 52-week range spans $0.64 to $5.20. Analyst consensus is buy with an average price target of $4.00. Rallies surfaces MXCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in MXCT news today?
MaxCyte Q1 Revenue $9.7M; Core Down 25%, SPL Up 62%, $10M Buyback: MaxCyte’s Q1 revenue totaled $9.7 million, with core revenue down 25% to $6.2 million and SPL Program revenue up 62% to $3.4 million, narrowing net loss to $4.8 million. The board approved a $10 million share repurchase and reaffirmed 2026 revenue guidance of $30–32 million, including $25–27 million in core sales.
MaxCyte Q1 Revenue $9.7M; Core Down 25%, SPL Up 62%, $10M Buyback: MaxCyte’s Q1 revenue totaled $9.7 million, with core revenue down 25% to $6.2 million and SPL Program revenue up 62% to $3.4 million, narrowing net loss to $4.8 million. The board approved a $10 million share repurchase and reaffirmed 2026 revenue guidance of $30–32 million, including $25–27 million in core sales.
Does Rallies summarize MXCT news?
Yes. Rallies summarizes MXCT news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is MXCT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for MXCT. It does not provide personalized investment advice.
